Skip to content

Author

S. Mandrekar

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

Summary Background Crizotinib is an established first-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of advanced ALK-positive non-small-cell lung cancer (NSCLC). E4512 aimed to evaluate the effect of adjuvant crizotinib on disease-free survival (DFS) in patients with resected, early-st...

D. E. Gerber, Yating Wang, C. Langer et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.